基于模型的药物相互作用外推策略:从成人到儿童脊髓性肌萎缩症患者中的利司扑兰
利司扑兰在体外呈时间依赖性抑制CYP3A,但儿童DDI研究不可行。研究者在健康成人中开展临床DDI研究,结合PBPK模型将DDI风险从成人外推至儿童SMA患者。PBPK分析提示利司扑兰对CYP3A的原发抑制主要发生在肠道而非肝脏,预测2月龄至18岁儿童患者中CYP3A抑制风险可忽略(咪达唑仑AUCR 1.09-1.18),该结果已纳入美国处方信息。
要点
- 利司扑兰对CYP3A的抑制主要在肠道而非肝脏。
- 预测儿童SMA患者中CYP3A抑制风险可忽略(咪达唑仑AUCR 1.09-1.18)。
- 该PBPK外推策略可用于指导儿科DDI评估。
核心结论
- PBPK模型分析提示利司扑兰对CYP3A的原发抑制发生在肠道而非肝脏。
- PBPK预测2月龄至18岁SMA儿童患者中利司扑兰的CYP3A抑制风险可忽略(咪达唑仑AUCR 1.09-1.18)。
- 该预测结果已纳入利司扑兰的美国处方信息。
研究设计与样本
- 在健康成人中开展临床DDI研究,利司扑兰暴露水平与儿童中观察到的相关暴露相当。
- 采用生理药代动力学(PBPK)模型,将DDI风险从健康成人迭代外推至儿童SMA患者。
- 儿童利司扑兰PBPK模型经独立数据验证,并与经验证的儿童咪达唑仑PBPK模型联合使用。
主要发现
- 利司扑兰使咪达唑仑AUC比值(AUCR)增加1.11倍。
- 与体外值相比,体内CYP3A失活常数低18倍。
- PBPK预测儿童SMA患者中咪达唑仑AUCR为1.09-1.18。
关键数值与推荐
- 临床DDI研究中利司扑兰导致的咪达唑仑AUCR为1.11。
- 体内CYP3A失活常数较体外值低18倍。
- PBPK预测2月龄至18岁儿童患者中咪达唑仑AUCR为1.09-1.18。
临床怎么用
- 基于PBPK预测,利司扑兰在2月龄至18岁SMA儿童患者中CYP3A抑制风险可忽略,无需因CYP3A抑制调整合并用药。
局限性
- 儿童DDI研究不可行,结论基于PBPK模型外推而非儿童直接临床DDI研究。
- 预测的CYP3A DDI对所选肠道和肝脏CYP3A个体发育函数的敏感性需综合评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Risdiplam (Evrysdi) improves motor neuron function in patients with spinal muscular atrophy (SMA) and has been approved for the treatment of patients ≥2 months old. Risdiplam exhibits time-dependent inhibition of cytochrome P450 (CYP) 3A in vitro. While many pediatric patients receive risdiplam, a drug-drug interaction (DDI) study in pediatric patients with SMA was not feasible. Therefore, a novel physiologically-based pharmacokinetic (PBPK) model-based strategy was proposed to extrapolate DDI risk from healthy adults to children with SMA in an iterative manner. A clinical DDI study was performed in healthy adults at relevant risdiplam exposures observed in children. Risdiplam caused an 1.11-fold increase in the ratio of midazolam area under the curve with and without risdiplam (AUCR)), suggesting an 18-fold lower in vivo CYP3A inactivation constant compared with the in vitro value. A pediatric PBPK model for risdiplam was validated with independent data and combined with a validated midazolam pediatric PBPK model to extrapolate DDI from adults to pediatric patients with SMA. The impact of selected intestinal and hepatic CYP3A ontogenies on the DDI susceptibility in children relative to adults was investigated. The PBPK analysis suggests that primary CYP3A inhibition by risdiplam occurs in the intestine rather than the liver. The PBPK-predicted risdiplam CYP3A inhibition risk in pediatric patients with SMA aged 2 months-18 years was negligible (midazolam AUCR of 1.09-1.18) and included in the US prescribing information of risdiplam. Comprehensive evaluation of the sensitivity of predicted CYP3A DDI on selected intestinal and hepatic CYP3A ontogeny functions, together with PBPK model-based strategy proposed here, aim to guide and facilitate DDI extrapolations in pediatric populations.
引用
- Cleary Y, Gertz M, Grimsey P, et al. Model-Based Drug-Drug Interaction Extrapolation Strategy From Adults to Children: Risdiplam in Pediatric Patients With Spinal Muscular Atrophy. Clin Pharmacol Ther. 2021. PMID: 34347881. doi:10.1002/cpt.2384
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。